TABLE 1.

Correlations of CLDN10 expression and clinicopathological significance in gastric cancer.

	OS PFS			PFS
	N	HR	p value	N	HR	p Value
Sex
Female	236	2.18(1.46–3.28)	0.0001	201	1.98(1.31–2.99)	0.00095
Male	544	1.64(1.32–2.04)	5.3544e-6	437	1.61(1.21–2.15)	0.00092
Stage
1	67	3.22(1.11–9.32)	0.023	60	2.37(0.77–7.3)	0.12
2	140	2.55(1.33–4.88)	0.0034	131	2.42(1.32–4.42)	0.0031
3	305	1.7(1.27–2.27)	3e-04	186	0.8(0.53–1.23)	0.31
4	148	1.66(1.07–2.59)	0.023	141	1.54(0.96–2.46)	0.073
Stage T
2	241	1.56(1.02–2.39)	0.037	239	1.59(1.05–2.41)	0.027
3	204	0.83(0.58–1.19)	0.31	204	0.77(0.55–1.1)	0.15
4	38	0.58(0.23–1.5)	0.26	39	0.61(0.24–1.51)	0.28
Stage N
0	74	3.06(1.25–7.48)	0.01	72	2.96(1.21–7.22)	0.013
1	225	2.01(1.26–3.2)	0.0028	222	1.84(1.18–2.88)	0.0063
2	121	0.88(0.54–1.43)	0.6	125	0.74(0.48–1.13)	0.16
3	76	1.82(1.03–3.22)	0.036	76	1.92(1.05–3.52)	0.032
1 + 2+3	422	1.33(1.02–1.74)	0.034	423	1.28(0.99–1.65)	0.059
Lauren classification
intestinal	320	2.15(1.55–2.98)	2.3e-06	263	1.6(1.13–2.27)	0.0079
diffuse	241	1.28(0.89–1.83)	0.1	231	1.18(0.82–1.69)	0.37
mixed	32	1.71(0.54–5.38)	0.36	28	0.43(0.15–1.21)	0.099
Treatment
surgery alone	380	1.54(1.08–2.19)	0.017	375	1.43(1.01–2.02)	0.044
5 FU based adjuvant	152	0.74(0.5–1.08)	0.12	152	0.73(0.49–1.08)	0.12
other adjuvant	86	0.37(0.15–0.89)	0.021	80	0.42(0.19–0.93)	0.028
HER2
negative	532	1.8(1.44–2.26)	2.1e-07	408	1.62(1.24–2.12)	0.00033
positive	343	1.25(0.95–1.64)	0.11	232	1.31(0.9–1.92)	0.16
Stage M
0	444	1.42(1.07–1.87)	0.013	443	1.35(1.03–1.76)	0.027
1	56	2(1.08–3.71)	0.024	56	1.82(0.97–3.39)	0.058

OS, overall survival; PFS, Progression-free survival, HR, Hazard ratio.